Navigation Links
ISIS Initiates Phase 1 Clinical Trial of ISIS-SOD1Rx in Patients With ALS
Date:3/5/2010

of drugs for neurodegenerative diseases, and the development, activity, therapeutic potential and safety of ISIS-SOD1Rx in the treatment of ALS.  Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement.  Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such products.  Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements.  Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis.  As a result, you are cautioned not to rely on these forward-looking statements.  These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2009, which is on file with the SEC.  Copies of this and other documents are available from the Company.

In this press release, unless the context requires otherwise, "Isis," "Company," "we," "our," and "us" refers to Isis Pharmaceuticals and its subsidiaries, including Regulus Therapeutics Inc.


'/>"/>
SOURCE Isis Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Kinex Pharmaceuticals Initiates a Phase 2 Clinical Trial of KX2-391 in Patients with Prostate Cancer
2. QRxPharma Initiates Second Pivotal Phase 3 Study of MoxDuo(TM)IR Dual-Opioid(TM) for NDA Submission
3. Daiichi Sankyo Initiates Largest Single, Double-Blind, Randomized, Phase III Trial for Treatment and Prevention of Recurrent Venous Thromboembolism
4. Celsis Initiates Patent Infringement Action Against XenoTech and Sekisui
5. Romark Initiates Clinical Trial of Alinia for Treatment of Influenza
6. Conatus Pharmaceuticals Initiates Phase II Clinical Trial in Combination With Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Virus (HCV)
7. ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases
8. Naurex Inc. Initiates Phase I Clinical Trial of its Novel Mechanism NMDA Modulator GLYX-13 in Treatment-Resistant Depression
9. Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma
10. ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis
11. Sangart, Inc. Initiates Phase IIa Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients With Hemorrhagic Shock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Jan. 14, 2014  Luminex Corporation (Nasdaq: LMNX ) ... fourth quarter of 2013 on Monday, February 3, 2014. A ... the close of trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ... discuss the operating highlights and financial results for the fourth ...
(Date:1/14/2014)... The Brandeis Medical Center, led by Dr. Emmanuel Brandeis , ... laser tattoo removal experience with the advanced Astanza Duality laser and ... quality cosmetic services with cutting edge medical technology and offering expert ... has seen a dramatic increase in the presence of ...
(Date:1/14/2014)... -- Acumed,s new SLIC Screw System - a jointed ... place and insert the screw accurately - offers surgeons ... repair or reconstruction as it holds the bones reduced ... http://photos.prnewswire.com/prnh/20140114/MN45636 ) The SLIC Screw is ...
Breaking Medicine Technology:Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3
... Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: ... congratulations to the four winners of the International BioGENEius ... an exemplary understanding of biotechnology through science research projects. ... Challenge since its inception in the early 1990s. Sanofi ...
... Shield LLC today announced the new SILVER STORM™ waterproof, ... with other infection prevention products, at the APIC infection ... been designed to help prevent cross contamination infections which ... According to a bacteria study of common touch ...
Cached Medicine Technology:Sanofi Pasteur Commends Winners of International BioGENEius Challenge 2Sanofi Pasteur Commends Winners of International BioGENEius Challenge 3
(Date:4/17/2014)... lost its status as the leading weapon against the ... life, with new research indicating it simply needs to ... use of the cheap anti-malarial drug chloroquine in treating ... of more than half a million people each year ... has developed resistance to chloroquine, but research carried out ...
(Date:4/16/2014)... the embryo. It begins as a glob of identical cells ... the cells of our lungs, muscles, nerves and all the ... feat of reverse tissue engineering, Stanford University researchers have begun ... to proliferate and transform into all of the specialized cells ...
(Date:4/16/2014)... 16, 2014): Celldex Therapeutics, Inc. (NASDAQ: CLDX) announced ... of CDX-1401 in solid tumors, including long-term patient follow-up, ... (Vol 6 Issue 232). The data demonstrate robust antibody ... in patients with very advanced cancers and suggest that ...
(Date:4/16/2014)... April 16, 2014 According to a new ... average-risk patients with one to two small polyps are ... cases. This may be an appropriate target for quality ... to quantify adherence to guidelines for timing of repeat ...
(Date:4/15/2014)... , Cases of diabetes and pre-diabetes in the United States ... Johns Hopkins Bloomberg School of Public Health, with obesity apparently ... the burden of the disease has not hit all groups ... the elderly. , According to new research reported in the ...
Breaking Medicine News(10 mins):Health News:Scientists find new way to fight malaria drug resistance 2Health News:Stanford scientists develop 'playbook' for reverse engineering tissue 2Health News:Stanford scientists develop 'playbook' for reverse engineering tissue 3Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 2Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 3Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 4Health News:Surveillance colonoscopy recommendations for average-risk patients with 1 to 2 small polyps consistent with guidelines 2Health News:Surveillance colonoscopy recommendations for average-risk patients with 1 to 2 small polyps consistent with guidelines 3Health News:Pre-diabetes and diabetes nearly double over the past 2 decades 2
... , ... ... ... ...
... ... ... , ... , , ...
... of the blood or hematopoietic system derive from stem cell ... to all the different kinds of blood cells equally, said ... a report that appears in the current issue of the ... "While previous reports in journals have hinted at ...
... preparation (ICCBco) in the treatment of lung lesions ... experimental animal model, a research group in China ... pathological changes and pathological effect mechanism of expression ... of portal hypertensive rabbits with schistosomiasis. ...
... In tests, novel immunotherapy appears to combat mesothelioma tumors ... vaccine for the asbestos-related cancer mesothelioma is safe, according ... tested the vaccine -- which infuses a patient,s own ... on 10 patients and found that it induced an ...
... , ... ... ... , ...
Cached Medicine News:Health News:'Less Is More' with the Innovation of Avemar(R) Fermented Wheat Germ Extract 2Health News:'Less Is More' with the Innovation of Avemar(R) Fermented Wheat Germ Extract 3Health News:'Less Is More' with the Innovation of Avemar(R) Fermented Wheat Germ Extract 4Health News:'Less Is More' with the Innovation of Avemar(R) Fermented Wheat Germ Extract 5Health News:Studies Detail Possible Benefits of omega-3 Fatty Acids for Dogs With Arthritis 2Health News:Studies Detail Possible Benefits of omega-3 Fatty Acids for Dogs With Arthritis 3Health News:Studies Detail Possible Benefits of omega-3 Fatty Acids for Dogs With Arthritis 4Health News:Theory of single stem cell for blood components challenged 2Health News:Treatment of portal hypertensive pulmonary lesions induced by schistosomiasis 2Health News:Vaccine for Asbestos-Related Cancer Looks Safe 2Health News:Hill-Rom Announces Second Quarter 2010 Dividend 2
With this more compact transducer face, this is the transducer of choice for obstetric imaging in areas with a small acoustic window....
Compact, bench-top analyser with minimal water volume requirements and easy waste management....
... The OPTI LION is a compact ... single-use cassettes instead of reagents or ... patient sample is analyzed., ,In addition ... the OPTI LION measures ionized calcium ...
... is precision, ergonomics, and value!, ... with soft non-slip, contoured handle , ... light plunger spring action , Completely ... without the need for recalibration , ...
Medicine Products: